
zzso zzso zzso is the first member of the zzso series of zzso zzso zzso It was selected for phase I testing because of high activity in the rat zzso zzso system and a possible novel site of zzso due to its small molecular zzso zzso zzso zzso was administered as a rapid zzso zzso infusion to 39 patients at doses ranging from 14 to 225 zzso zzso and vomiting were not severe but total zzso occurred in the majority of patients at doses greater than 100 zzso The zzso toxic effect was zzso which was cumulative with lower, more prolonged zzso following successive zzso The median time to zzso count zzso was 21 days, with recovery by 35 zzso A minor response was seen in one patient with an zzso of the zzso The recommended dose for phase II studies is 125 zzso for patients who have received prior chemotherapy and 150 zzso for those who have not, in an every zzso zzso 

